{
    "id": 26562,
    "fullName": "IGH - MYC",
    "impact": "fusion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "IGH-MYC results from the fusion of IGH and MYC, resulting in increased activity of Myc, thereby potentially driving oncogenisis (PMID: 17639584).",
            "references": [
                {
                    "id": 8874,
                    "pubMedId": 17639584,
                    "title": "In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17639584"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3492,
        "geneSymbol": "IGH",
        "terms": [
            "IGH",
            "IGD1",
            "IGH.1@",
            "IGH@",
            "IGHD@",
            "IGHDY1",
            "IGHJ",
            "IGHJ@",
            "IGHV",
            "IGHV@"
        ]
    },
    "variant": "IGH - MYC",
    "createDate": "05/11/2017",
    "updateDate": "05/11/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4609,
                "geneSymbol": "MYC",
                "terms": [
                    "MYC",
                    "bHLHe39",
                    "c-Myc",
                    "MRTL",
                    "MYCC"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 10874,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a Burkitt lymphoma cell line harboring IGH-MYC demonstrated decreased cell viability when treated with GMX1778 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 27814,
                "profileName": "IGH - MYC"
            },
            "therapy": {
                "id": 5666,
                "therapyName": "GMX1778",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10873,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a Burkitt lymphoma cell line harboring IGH-MYC demonstrated decreased cell viability when treated with FK866 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 27814,
                "profileName": "IGH - MYC"
            },
            "therapy": {
                "id": 5662,
                "therapyName": "FK866",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12347,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cytosar-U (cytarabine) treatment combined with Talazoparib (BMN-673) in IGH-MYC positive Burkitt lymphoma cell line xenograft models resulted in a synergistic effect, demonstrating a greater reduction in IGH-MYC positive Burkitt lymphoma cells and an improved survival compared to treatment with either agent alone (PMID: 28634224).",
            "molecularProfile": {
                "id": 27814,
                "profileName": "IGH - MYC"
            },
            "therapy": {
                "id": 6468,
                "therapyName": "Cytarabine + Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10338,
                    "pubMedId": 28634224,
                    "title": "IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28634224"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12346,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Burkitt lymphoma cells with decreased expression of BRCA2 and harboring IGH-MYC demonstrated decreased survival when treated with Talazoparib (BMN-673) in culture (PMID: 28634224).",
            "molecularProfile": {
                "id": 28678,
                "profileName": "IGH - MYC BRCA2 dec exp"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10338,
                    "pubMedId": 28634224,
                    "title": "IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28634224"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12345,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Burkitt lymphoma cells with decreased expression of BRCA2 and harboring IGH-MYC demonstrated decreased survival when treated with Lynparza (olaparib) in culture (PMID: 28634224).",
            "molecularProfile": {
                "id": 28678,
                "profileName": "IGH - MYC BRCA2 dec exp"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10338,
                    "pubMedId": 28634224,
                    "title": "IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28634224"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27814,
            "profileName": "IGH - MYC",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28678,
            "profileName": "IGH - MYC BRCA2 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}